Alzheimer’s Biomarkers For Disease Progression Will Be A Hard Road, Experts Say
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A panel of experts discussing challenges in researching disease-progression biomarkers for Alzheimer’s agreed that the heterogeneity and evolving nature of the disease complicate the task and may require large panels of biomarkers – a potentially costly and invasive solution.
You may also be interested in...
Observational Studies Reveal Commonalities Across Neurodegenerative Disorders Like Parkinson’s And Alzheimer’s
It’s all about biomarkers, biomarkers, biomarkers as huge cohort studies amass data in the hunt for clues that can aid in drug development, and the rising tide may lift more than one boat as commonalities among diseases like Alzheimer’s and Parkinson’s are discovered.
Lilly Expands Bet on Tau By Buying Siemens’ Alzheimer’s Imaging Portfolio
The acquisition of a tau PET imaging portfolio from Siemens further expands Lilly’s Alzheimer’s program.
Guidance For Drugs To Target Early Alzheimer’s Notes Lack Of Metrics, Biomarkers
FDA’s new draft guidance on developing drugs to treat people in the early stages of Alzheimer’s disease, before any noticeable dementia sets in, is sure to generate further discussion and comment on how best to identify and measure the disease and its progression.